These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 7666086

  • 1. p53 mutations in benign breast tissue.
    Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ.
    J Clin Oncol; 1995 Sep; 13(9):2293-300. PubMed ID: 7666086
    [Abstract] [Full Text] [Related]

  • 2. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.
    Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ, Liu ET, Conway K.
    J Clin Oncol; 2000 Jan; 18(2):267-74. PubMed ID: 10637239
    [Abstract] [Full Text] [Related]

  • 3. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
    Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, Van Zee KJ.
    Cancer; 2000 Dec 01; 89(11):2153-60. PubMed ID: 11147584
    [Abstract] [Full Text] [Related]

  • 4. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
    Alexiev BA, Bassarova AV, Popovska SL, Popov AA, Christov CZ.
    Gen Diagn Pathol; 1997 Jun 01; 142(5-6):271-9. PubMed ID: 9228249
    [Abstract] [Full Text] [Related]

  • 5. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H.
    Cancer; 1997 Feb 15; 79(4):700-16. PubMed ID: 9024708
    [Abstract] [Full Text] [Related]

  • 6. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer.
    Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R.
    Clin Cancer Res; 1998 Jul 15; 4(7):1597-602. PubMed ID: 9676832
    [Abstract] [Full Text] [Related]

  • 7. Sarcoglycans in the normal and pathological breast tissue of humans: an immunohistochemical and molecular study.
    Arco A, Favaloro A, Gioffrè M, Santoro G, Speciale F, Vermiglio G, Cutroneo G.
    Cells Tissues Organs; 2012 Jul 15; 195(6):550-62. PubMed ID: 22067288
    [Abstract] [Full Text] [Related]

  • 8. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
    Supanaranond K, Sukarayodhin S, Tanyakaset M, Balachandra K, Jullaksorn D, Rienkijkarn M, Hoisanka N, Tantivanich S.
    Southeast Asian J Trop Med Public Health; 1997 Sep 15; 28(3):631-40. PubMed ID: 9561622
    [Abstract] [Full Text] [Related]

  • 9. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
    Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL.
    J Clin Oncol; 2004 Jan 01; 22(1):86-96. PubMed ID: 14701769
    [Abstract] [Full Text] [Related]

  • 10. p53 protein accumulation and mutations in normal and benign breast tissue.
    Kandel R, Li SQ, Ozcelik H, Rohan T.
    Int J Cancer; 2000 Jul 01; 87(1):73-8. PubMed ID: 10861455
    [Abstract] [Full Text] [Related]

  • 11. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C.
    Clin Cancer Res; 2002 Jan 01; 8(1):171-9. PubMed ID: 11801555
    [Abstract] [Full Text] [Related]

  • 12. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA.
    Anticancer Res; 2005 Jan 01; 25(1B):635-41. PubMed ID: 15816639
    [Abstract] [Full Text] [Related]

  • 13. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study.
    Rohan TE, Li SQ, Hartwick R, Kandel RA.
    Cancer Epidemiol Biomarkers Prev; 2006 Jul 01; 15(7):1316-23. PubMed ID: 16835330
    [Abstract] [Full Text] [Related]

  • 14. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.
    Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, Kandel RA, Glass AG, Rohan TE.
    Cancer Causes Control; 2010 Jun 01; 21(6):821-8. PubMed ID: 20084540
    [Abstract] [Full Text] [Related]

  • 15. P53 expression in patients with malignant and benign breast diseases.
    Kalogeraki A, Panayiotides J, Tamiolakis D, Tzardi M, Chaniotis V, Chalkiadakis G, Melissas J, Stiftsis D, Kanavaros P, Delides GS.
    Anticancer Res; 2000 Jun 01; 20(3A):1801-5. PubMed ID: 10928110
    [Abstract] [Full Text] [Related]

  • 16. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
    Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS.
    Cancer Res; 1994 Aug 15; 54(16):4342-6. PubMed ID: 8044781
    [Abstract] [Full Text] [Related]

  • 17. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene.
    Evers BM, Rady PL, Sandoval K, Arany I, Tyring SK, Sanchez RL, Nealon WH, Townsend CM, Thompson JC.
    Ann Surg; 1994 Jun 15; 219(6):596-601; discussion 602-4. PubMed ID: 7911296
    [Abstract] [Full Text] [Related]

  • 18. Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer.
    Werenskiold AK, Prechtel D, Harbeck N, Höfler H.
    Diagn Mol Pathol; 2000 Mar 15; 9(1):26-34. PubMed ID: 10718210
    [Abstract] [Full Text] [Related]

  • 19. p53 mutations and expression in breast carcinoma in situ.
    Lukas J, Niu N, Press MF.
    Am J Pathol; 2000 Jan 15; 156(1):183-91. PubMed ID: 10623666
    [Abstract] [Full Text] [Related]

  • 20. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ, Arneson NC, Ozçelik H, Redston M, Andrulis IL.
    Cancer Res; 1998 Feb 15; 58(4):785-9. PubMed ID: 9485035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.